Lu AF35700 (Lundbeck) Drug Overview - A Novel Pharmacological Profile as a Dopamine D1 and D2 Antagonist With a High Occupancy of 5-HT2A and 5-HT6 Serotonin Receptors - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: Lu AF35700" report has been added to ResearchAndMarkets.com's offering.

Lu AF35700 (Lundbeck) has a novel pharmacological profile as a dopamine D1 and D2 antagonist with a high occupancy of 5-HT2A and 5-HT6 serotonin receptors. The relatively low D2 receptor occupancy of Lu AF35700, compared to at the D1 receptor, is expected to result in a diminished burden of side effects such as depressed mood, extrapyramidal symptoms, prolactin elevation, and anhedonia.

Lu AF35700 is a novel prospect for treatment-resistant schizophrenia. The drug is designed to be well tolerated compared to existing atypical antipsychotic therapies, hence Lundbeck is positioning its pipeline drug to help address unmet need in the schizophrenia market. The author awaits further developments for Lu AF35700, as available clinical trial data are limited to Phase I thus far.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Lu AF35700: Schizophrenia

List of Figures

Figure 1: Lu AF35700 for schizophrenia - SWOT analysis

List of Tables

Table 1: Lu AF35700 drug profile

Table 2: Lu AF35700 Phase II and Phase III trials in schizophrenia

For more information about this report visit https://www.researchandmarkets.com/research/pjvrj4/lu_af35700?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900